Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Fragile X Syndrome: early-phase trial registry

7 of 17 indexed Fragile X Syndrome trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,004 of 28,707 conditions by registered trial count.

17 US clinical trials · 7 currently recruiting · #1,004 of 28,707 conditions by registered trial count

Fragile X Syndrome: 17 US clinical trials tracked, 7 recruiting.

Fragile X Syndrome is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Hospital Medical Center, Cincinnati, running 7 of these trials.

Enrollment posture brief

Registry condition fragile-x-syndrome

OPEN 7 | RECR 41% | LATE 2 | EARLY 7 | RANK #1004 | SPON 7

Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)

Acute Myeloid Leukemia, in R70.6%Abdominal Aortic Aneurysm52.9%Fragile X Syndrome (this)41%Acute Lymphoblastic Leukemia23.5%Actinic Keratosis11.8%
Open-enrollment share among volume-matched conditions near Fragile X Syndrome

Fragile X Syndrome lists 7 open slots (41% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Fragile X Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Fragile X Syndrome is recruiting below its size-band peers.

    7 of 17 indexed trials (41.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Fragile X Syndrome research.

    Children's Hospital Medical Center, Cincinnati accounts for 7 of 17 trials (41.2%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Most Fragile X Syndrome trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 17 trials that report a genuine target (sentinel values excluded). 13 of those (76.5%) plan for fewer than 100 participants.

  4. Fragile X Syndrome research is mostly interventional.

    16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 24Phase 32

Open and recent trials

17 total, page 1 of 1

RECRUITING NA 376 participants

Physical Activity and Community EmPOWERment Project

University of North Carolina, Chapel Hill

NCT06740162

RECRUITING NA 180 participants

Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders

Children's Hospital Medical Center, Cincinnati

NCT06227780

RECRUITING NA 92 participants

Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)

Rush University Medical Center

NCT06139172

RECRUITING NA 90 participants

Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age

Children's Hospital Medical Center, Cincinnati

NCT05957549

RECRUITING NA 60 participants

Speech-in-noise Perception in Autism and Fragile X

Children's Hospital Medical Center, Cincinnati

NCT06088589

RECRUITING Phase 2 60 participants

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

Mirum Pharmaceuticals

NCT07209462

RECRUITING NA 30 participants

Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant

Children's Hospital Medical Center, Cincinnati

NCT06560242

ACTIVE NOT RECRUITING Phase 3 314 participants

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

Tetra Discovery Partners

NCT05367960

ACTIVE NOT RECRUITING Phase 2 45 participants

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

Children's Hospital Medical Center, Cincinnati

NCT05418049

COMPLETED Phase 3 125 participants

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome

Seaside Therapeutics

NCT01282268

COMPLETED 96 participants

Pediatric Patients With Metabolic or Other Genetic Disorders

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NCT02769949

COMPLETED NA 66 participants

Trial of Minocycline to Treat Children With Fragile X Syndrome

University of California, Davis

NCT01053156

COMPLETED Early Phase 1 29 participants

Neurophysiological and Acute Pharmacological Studies in FXS Patients

Children's Hospital Medical Center, Cincinnati

NCT02998151

COMPLETED Phase 1 21 participants

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

Novartis Pharmaceuticals

NCT01482143

COMPLETED Phase 1 15 participants

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

Children's Hospital Medical Center, Cincinnati

NCT03140813

COMPLETED Phase 2 15 participants

ERG/5-HTP in Fragile X Syndrome (FXS)

Elizabeth Berry-Kravis

NCT05030129

COMPLETED Phase 2 14 participants

Acamprosate in Youth With Fragile X Syndrome

Indiana University

NCT01300923

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 4
Phase 3 2

Named interventions

Most-linked intervention names on Fragile X Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Baclofen Drug
2 trials
Acamprosate Drug
2 trials
Speech discrimination Other
2 trials
Matching placebo for 5-Hydroxytryptophan Drug
1 trials
Matching placebo for Ergoloid mesylates Drug
1 trials
Ergoloid Mesylates Drug
1 trials
AZD7325 (Low-Dose) Drug
1 trials

US sites by state

Facility locations filed on Fragile X Syndrome trials. A trial with sites in several states counts in each.

Ohio 10 trials
Illinois 6 trials
California 5 trials
Maryland 4 trials
Pennsylvania 3 trials
Massachusetts 3 trials
Georgia 3 trials
Florida 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Fragile X Syndrome page

17 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fragile X Syndrome condition card totals 17 registered trials; most-linked intervention Placebo; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.